Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms
- 1State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease driven by both metabolic stress and immune dysregulation. A growing body of evidence suggests that adaptive immune cells exhibit significant functional plasticity during the progression and resolution of MASH. CD8+ T cells can assume various states, including pathogenic cytotoxicity, functional exhaustion, and tissue repair; CD4+ T cells exhibit enhanced Th1/Th17 programming, reduced Treg stability, and a functional shift toward Th17/Treg; and B cells undergo remodeling between regulatory, pro-inflammatory, and antibody-effect states. These functional states determine disease outcomes through distinct effector mechanisms. The cytotoxicity and inflammatory factors of pathogenic T cells promote hepatocyte damage, metabolic dysregulation, and hepatocyte stellate cell activation, while B-cell antigen presentation, cytokine, and antibody responses further amplify inflammation and fibrosis; conversely, Tregs, Bregs, and tissue-resident CD8+ T cells with reparative functions can limit inflammation or promote the resolution of fibrosis. Adaptive immune plasticity is, in turn, continuously shaped by the hepatic metabolic environment, in which glycolipid and mitochondrial metabolic reprogramming determine the metabolic basis of different functional states, while metabolite-driven epigenetic remodeling stabilizes corresponding transcriptional programs. Microbiome components and metabolic signals originating from the gut-liver axis further regulate the state of T and B cells within the liver. Consequently, the functional states of adaptive immune cells, their pathological effects, and their metabolic regulation collectively constitute a critical immunometabolic network linking metabolic dysregulation, chronic inflammation, and the progression of fibrosis, providing a unified mechanistic framework for understanding the sustained progression of MASH and tissue repair.
Related
- Epithelial-mesenchymal transition plasticity in breast cancer: regulatory mechanisms and therapeutic implications
- Central and peripheral plasticity after chemical unilateral labyrinthectomy: Glial responses, calyces dynamics, and behavioral consequences
- Cannabinoid CB1 Receptor Regulates Spinal Dorsal Horn Synaptic Plasticity in a Mouse Model of Neuropathic Pain through the CB1R/SREBP1/NAMPT/SIRT1 Metabolic Regulatory Framework
- Chronic Occupational Stress and Immune–Inflammatory Dysregulation: Mechanisms, Clinical Consequences, Biomarkers and Implications for Occupational Medicine
- Molecular and microenvironmental networks driving tumor dormancy: pathological mechanisms and emerging clinical strategies
BibTeX
@article{yu2026adaptive,
title = {{Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms}},
author = {Xiayu Yu and Yuxuan Yang and Lan Bai},
journal = {Hepatology communications},
year = {2026},
month = oct,
doi = {10.1097/hc9.0000000000001075},
url = {https://europepmc.org/article/PMC/PMC13694069},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms
AU - Xiayu Yu
AU - Yuxuan Yang
AU - Lan Bai
PY - 2026
DA - 2026/10/23
JO - Hepatology communications
DO - 10.1097/hc9.0000000000001075
UR - https://europepmc.org/article/PMC/PMC13694069
AB - Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease driven by both metabolic stress and immune dysregulation. A growing body of evidence suggests that adaptive immune cells exhibit significant functional plasticity during the progression and resolution of MASH. CD8+ T cells can assume various states, including pathogenic cytotoxicity, functional exhaustion, and tissue repair; CD4+ T cells exhibit enhanced Th1/Th17 programming, reduced Treg stability, and a functional shift toward Th17/Treg; and B cells undergo remodeling between regulatory, pro-inflammatory, and antibody-effect states. These functional states determine disease outcomes through distinct effector mechanisms. The cytotoxicity and inflammatory factors of pathogenic T cells promote hepatocyte damage, metabolic dysregulation, and hepatocyte stellate cell activation, while B-cell antigen presentation, cytokine, and antibody responses further amplify inflammation and fibrosis; conversely, Tregs, Bregs, and tissue-resident CD8+ T cells with reparative functions can limit inflammation or promote the resolution of fibrosis. Adaptive immune plasticity is, in turn, continuously shaped by the hepatic metabolic environment, in which glycolipid and mitochondrial metabolic reprogramming determine the metabolic basis of different functional states, while metabolite-driven epigenetic remodeling stabilizes corresponding transcriptional programs. Microbiome components and metabolic signals originating from the gut-liver axis further regulate the state of T and B cells within the liver. Consequently, the functional states of adaptive immune cells, their pathological effects, and their metabolic regulation collectively constitute a critical immunometabolic network linking metabolic dysregulation, chronic inflammation, and the progression of fibrosis, providing a unified mechanistic framework for understanding the sustained progression of MASH and tissue repair.
SN - 2471-254X
ER -